目的：探讨新型鼻腔泪囊吻合术联合丙酸氟替卡松治疗慢性泪囊炎患者的疗效。

方法：前瞻性研究。选择2021-01/2022-12我院收治的慢性泪囊炎患者100例100眼，依据患者入院顺序编号分为对照组50眼(行新型鼻腔泪囊吻合术治疗)和观察组50眼(行新型鼻腔泪囊吻合术联合丙酸氟替卡松治疗)。比较两组患者手术前后最佳矫正视力(BCVA)、生活质量评分以及复发情况。

结果：所有患者均完成术后6 mo随访，观察组患者术后总有效率优于对照组(98% vs 84%，P=0.001)，手术前后BCVA比较无差异(P>0.05)。术前两组患者生活质量评分比较无差异(P>0.05)，术后6 mo，对照组患者的躯体功能、心理功能、社会功能和物质生活状态评分均比观察组低(均P<0.001)。术后6 mo，对照组复发9眼(18%)，观察组复发1眼(2%)，两组比较有差异(χ²=-2.739，P=0.001)。

结论：新型鼻腔泪囊吻合术联合丙酸氟替卡松治疗慢性泪囊炎患者效果佳，可以提高患者的生活质量，降低复发率。

METHODS: A total of 100 patients(100 eyes)with chronic dacryocystitis who admitted to our hospital between January 2021 and December 2022 were enrolled in the prospective study. The patients in the study were divided into a control group(n=50)and an observation group(n=50)based on their admission order and number. Patients in the control group were treated with novel rhinodacryocystostomy, while patients in the observation group were treated with a new type of rhinodacryocystostomy combined with fluticasone propionate. The preoperative and postoperative best corrected visual acuity(BCVA), quality of life score, and recurrence of chronic dacryocystitis were compared between the two groups of patients.

RESULTS: All patients completed the postoperative 6 mo follow-up, and the total effective rate of patients in the observation group was better than that of patients in the control group(98% vs 84%, P=0.001). There was no significant difference in preoperative and postoperative BCVA between the two groups(P>0.05). Preoperatively, there was no significant difference in the quality of life scores between the two groups of patients(P>0.05); At 6 mo postoperatively, the quality of life scores of patients in the control group, including physical function, psychological function, social function, and material life status, were lower than those in the observation group(all P<0.001). There were 9 recurrences in the control group(18%)and 1 in the observation group(2%), and there was statistical significance in the postoperative recurrence rate between the two groups(χ²=-2.739, P=0.001).

CONCLUSION: The new type of rhinodacryocystostomy combined with fluticasone propionate treatment for chronic dacryocystitis patients has a good therapeutic effect, can improve the quality of life of patients, and reduce the probability of disease recurrence.